Heron Therapeutics, based in San Diego, develops pharmaceutical products for acute care and oncology, including SUSTOL, CINVANTI, ZYNRELEF, and APONVIE, with 126 employees. Its products are distributed in the U.S.
Heron Therapeutics (HRTX) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Heron Therapeutics's actual EPS was -$0.03, beating the estimate of -$0.03 per share, resulting in a 11.76% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
